NEW YORK (GenomeWeb News) – SQI Diagnostics' fiscal first quarter revenues declined 25 percent year over year, the company reported after the close of the market on Thursday.

For the three months ended Dec. 31, 2012, revenues dropped to C$3,000 (US$2,980) from C$4,000 a year ago, the Toronto-based company said in a document filed with Canadian regulators. All revenues derived from product sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.